Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, discusses key differences between disease modifying effects and symptomatic effects and how to distinguish between these in clinical trials. Dr Hendrix explains that disease modifying effects are important in the case of degenerative diseases, and further highlights the need to accurately analyze data to capture these effects. To conclude, Dr Hendrix summarizes analysis methods and study designs used to separate these effects, including randomized withdrawal and delayed-start designs. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
